Project Grant R00HL165099
Award Date
8/12/24
Completion Date
7/31/27
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,408,580 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary objective is to investigate whether activating this pathway can restore contractile function in human induced pluripotent stem cell cardiomyocytes with DCM-causing mutations, and whether it can mitigate clinical...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University provides $159,512.00 to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM), a leading cause of heart failure. The research will utilize induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with DCM mutations to study how impaired proteostasis and endoplasmic reticulum stress...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,387 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Colorado-Denver. The grant, with a project period from January 1, 2025 to December 31, 2029, aims to investigate the role of miR-301B in regulating autophagy and its impact on cardiac function in pediatric dilated cardiomyopathy (DCM). The key objectives are to: 1) Determine the expression levels of autophagy-related proteins...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $159,512 to The Leland Stanford Junior University to conduct research aimed at mitigating the detrimental effects of cardiac fibrosis in dilated cardiomyopathy (DCM). The research will utilize advanced techniques such as whole genome sequencing, single nucleus RNA sequencing, and ATAC sequencing on a panel of diverse human induced pluripotent stem cell-derived...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $711,039 to the Research Institute at Nationwide Children's Hospital to investigate the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the methyltransferases METTL3 and METTL14 in embryonic mouse myocardium, and identify the molecular mechanisms by which they...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $618,045 project grant (R01HL172871) to the University of Arizona to conduct research on identifying new mechanisms and targets for early onset diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research, spanning from December 2024 to November 2028, aims to fully characterize three functional domains of the cardiac thin filament linked to the regulation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $116,250.00 to the Regents of the University of Minnesota to conduct research on identifying the underlying causes of cardiomyopathy. The research aims to evaluate the use of cardiac magnetic resonance imaging to reclassify the causes of cardiomyopathy, which could lead to more accurate diagnosis and appropriate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $243,000.00 to the University of Cincinnati to develop innovative RNA biodevices that integrate CRISPR and ADAR gene-editing technologies. The goal is to precisely modulate fibroblast cells to boost cardiac reprogramming and improve treatment for myocardial infarction-induced cardiovascular diseases. Specifically, the research aims to engineer an RNA scaffold to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to the Broad Institute of MIT and Harvard to study the genetic basis and underlying mechanisms of heart failure. The award will leverage high-throughput functional genomic assays, including cell painting and Perturb-seq, to systematically link genetic risk loci associated with heart failure to specific molecular and cellular...